COPPER HISTIDINATE - Generic Drug Details

« Back to Dashboard

What are the generic sources for copper histidinate and what is the scope of patent protection?

Copper histidinate is the generic ingredient in one branded drug marketed by Sentynl Theraps Inc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for COPPER HISTIDINATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	2
Patent Applications:	103
What excipients (inactive ingredients) are in COPPER HISTIDINATE?	COPPER HISTIDINATE excipients list
DailyMed Link:	COPPER HISTIDINATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for COPPER HISTIDINATE

Constraining patent/regulatory exclusivity:

TREATMENT OF MENKES DISEASE IN PEDIATRIC PATIENTS

Dosage:

POWDER;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for COPPER HISTIDINATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Stephen G. Kaler, MD	Phase 1/Phase 2
Cyprium Therapeutics, Inc.	Phase 3
National Center for Complementary and Integrative Health (NCCIH)	Phase 3

See all COPPER HISTIDINATE clinical trials

US Patents and Regulatory Information for COPPER HISTIDINATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sentynl Theraps Inc	ZYCUBO	copper histidinate	POWDER;SUBCUTANEOUS	211241-001	Jan 12, 2026		RX	Yes	Yes
Sentynl Theraps Inc	ZYCUBO	copper histidinate	POWDER;SUBCUTANEOUS	211241-001	Jan 12, 2026		RX	Yes	Yes

Copper Histidinate Market Dynamics, Patent Position, FDA Status, and Financial Trajectory

Last updated: September 24, 2026

Copper histidinate is an investigational treatment for Menkes disease, a rare X-linked disorder of copper transport. The leading development program is CUTX-101, developed by Cyprium Therapeutics, a Fortress Biotech company. Through the latest broadly reported public filings and regulatory disclosures available for this analysis, copper histidinate had no FDA-approved product revenue, no established Orange Book listing, and no commercial generic market.

The investment case depends on three variables: FDA approval, the ability to manufacture and distribute a chronic injectable orphan drug, and pricing relative to a very small patient population. If approved, copper histidinate could achieve orphan-drug pricing and rapid uptake among diagnosed patients, but its absolute revenue ceiling would remain constrained by Menkes disease prevalence.

What is copper histidinate used to treat?

Copper histidinate is designed to replace copper in patients with Menkes disease. Menkes disease results from pathogenic variants in the ATP7A gene, which disrupt copper transport and cause systemic copper deficiency. The disease primarily affects male infants and often causes seizures, developmental impairment, hypotonia, failure to thrive, hypopigmentation, and progressive neurologic damage.

Copper histidinate is administered by subcutaneous injection. Early treatment is critical because copper replacement may prevent or reduce neurologic injury when started before irreversible damage develops.

How does copper histidinate compare with existing Menkes treatments?

There is no broadly effective oral copper therapy for classic Menkes disease because the underlying transport defect limits copper absorption and distribution. Copper replacement may be administered under specialist supervision using parenteral copper products, including copper histidinate or other copper salts obtained through compounding, investigational access, or institutional protocols.

CUTX-101 is intended to provide a standardized, pharmaceutical-grade, commercially distributed formulation. Its commercial value therefore depends partly on replacing fragmented access to noncommercial copper preparations rather than displacing a large branded medicine.

Factor	Copper histidinate	Oral copper salts	Copper chloride or other parenteral copper
Intended population	Menkes disease	Limited utility in classic disease	Specialist and institutional use
Delivery	Subcutaneous injection	Oral	Usually intravenous or other parenteral administration
Commercial standardization	Intended through CUTX-101	Variable	Variable
FDA-approved Menkes indication	Not established through the latest public status reviewed	No established approval for classic Menkes disease	No established branded Menkes approval
Main clinical limitation	Early diagnosis and chronic injections	Defective copper transport	Administration burden and formulation limitations

What is the FDA regulatory status of copper histidinate?

Copper histidinate remained an investigational product in the latest public regulatory status reviewed. Cyprium has pursued CUTX-101 through the FDA orphan-drug framework and has reported FDA interactions involving the product’s New Drug Application.

The regulatory pathway has included orphan-drug development, rare-disease clinical evidence, and FDA review of a proposed commercial formulation. Menkes disease has a small and medically urgent patient population, so the regulatory package relies on limited but clinically meaningful evidence rather than the large randomized trials typical of common diseases.

Does copper histidinate have FDA approval?

No approved FDA commercial status was established in the public record reviewed for this analysis. Until approval occurs, copper histidinate does not have an FDA-approved label, an approved commercial indication, or an Orange Book-listed reference product.

Regulatory approval would change the market structure in several ways:

1. CUTX-101 could become the first standardized branded copper replacement product specifically positioned for Menkes disease.
2. The sponsor could seek reimbursement through specialty pharmacy, hospital, and rare-disease channels.
3. Potential generic applicants would need to address the product’s injectable formulation, manufacturing process, and regulatory exclusivity.
4. The sponsor could pursue post-approval expansion into additional copper-transport disorders if supported by clinical evidence.

When could copper histidinate lose exclusivity?

Copper histidinate does not have a reliable commercial exclusivity-loss date while the product remains unapproved. The effective protection period would depend on FDA approval timing, applicable orphan-drug exclusivity, regulatory exclusivity, and patent claims.

For an approved rare-disease product, seven years of U.S. orphan-drug exclusivity generally runs from approval of the designated indication under the Orphan Drug Act. This period blocks FDA approval of the same drug for the same disease from another sponsor, subject to statutory exceptions. Orphan exclusivity is separate from patent protection and does not prevent all forms of competition.

A copper histidinate product could also receive:

• Five years of new chemical entity exclusivity if the FDA classifies the active ingredient as eligible.
• Three years of clinical-investigation exclusivity for certain changes supported by new clinical studies.
• Patent term adjustment or patent term extension, subject to statutory limits.
• Pediatric exclusivity if qualifying pediatric studies are completed.

The key commercial date is therefore not a fixed patent expiration date. It is the later of relevant patent barriers and regulatory exclusivity, adjusted for the specific dosage form and indication.

What patents protect copper histidinate?

The public commercial record identifies intellectual-property protection around the use of copper histidinate for Menkes disease, pharmaceutical formulations, dosing, and administration. Patent protection is likely to be more important for formulation and method-of-use claims than for the basic concept of administering copper to a copper-deficient patient.

A complete patent-family analysis requires claim-by-claim review of the USPTO, WIPO, and relevant foreign registers. Public company disclosures do not establish a single definitive expiration date for every potentially relevant claim.

What types of patent claims matter most?

Patent category	Commercial purpose	Risk profile
Composition or formulation claims	Protect the injectable copper-histidinate product	Stronger if the approved formulation falls within the claims
Method-of-use claims	Protect treatment of Menkes disease, dosing, or early intervention	Important where the indication is narrow and orphan-focused
Manufacturing claims	Protect purity, complexation, sterilization, concentration, or process controls	Can raise technical barriers for follow-on manufacturers
Device or administration claims	Protect prefilled syringes, dosing systems, or injection schedules	Usually narrower and easier to design around
Data and regulatory exclusivity	Delay approval of competing products	Time-limited and separate from patents

No reliable public basis establishes an Orange Book patent listing before FDA approval. If CUTX-101 is approved, the sponsor could list eligible patents covering the drug substance, formulation, method of use, or delivery system. Non-listable manufacturing patents could remain relevant in patent litigation but would not necessarily produce the same regulatory effect.

Are there Paragraph IV challenges to copper histidinate?

No public Paragraph IV challenge or ANDA litigation was established in the record reviewed. That result is commercially expected for an investigational orphan drug with no approved reference product.

A generic challenge would become more plausible only after:

1. FDA approval of a reference product.
2. Publication of an Orange Book listing.
3. A sufficiently attractive price and patient population.
4. A viable pathway for demonstrating pharmaceutical equivalence and therapeutic equivalence.

The small market could discourage conventional generic manufacturers. A competitor might instead challenge method-of-use patents, develop an alternative copper formulation, or pursue a separate 505(b)(2) application.

How strong is the copper histidinate patent estate?

The estate appears commercially meaningful but narrow. Its strength is likely to come from regulatory exclusivity, orphan-disease positioning, manufacturing know-how, and physician adoption rather than from broad composition-of-matter protection alone.

Strengths

• The disease is rare and clinically severe.
• Early diagnosis creates a strong rationale for treatment soon after birth.
• A standardized injectable product could replace inconsistent access to compounded or investigational copper preparations.
• Manufacturing and quality-control requirements may deter small competitors.
• Orphan-drug exclusivity could protect the approved indication even if patent scope is limited.

Weaknesses

• The patient population is very small.
• The underlying active ingredient is a copper-amino-acid complex, which may limit broad composition claims.
• Competitors could attempt alternative copper salts or delivery routes.
• Treatment must begin early, making newborn screening and diagnosis central to market penetration.
• Chronic injections create adherence, caregiver, and reimbursement barriers.

What is the market size for copper histidinate?

The addressable market is small in patient count but potentially high in revenue per patient. Menkes disease incidence estimates vary by population and case ascertainment, with commonly cited estimates ranging from approximately one case per 34,000 male births to substantially lower rates in broader population estimates (Kaler, 2011).

The annual U.S. incident population is likely measured in dozens rather than thousands. The treated prevalent population could be larger because some patients survive into childhood or adulthood, but severe classic Menkes disease has high early mortality and substantial neurologic disability.

A commercial revenue framework can be expressed as follows:

Scenario	Treated U.S. patients	Net annual revenue per patient	Estimated U.S. product revenue
Low	50	$100,000	$5 million
Base	100	$200,000	$20 million
High	200	$300,000	$60 million

These are scenario values, not reported company guidance. Actual revenue would depend on diagnosis rates, payer approval, dosing, treatment duration, patient weight, international access, discounts, and patient-assistance programs.

The commercial opportunity could be larger if the product gains use in patients with atypical ATP7A variants, milder phenotypes, or other disorders involving copper transport. Those opportunities would require clinical and regulatory support.

What is the financial trajectory for copper histidinate?

Copper histidinate had no independently reported product sales in the latest public information reviewed. Its financial trajectory is therefore best analyzed as a development-stage asset rather than a mature pharmaceutical franchise.

Pre-approval phase

Before approval, the program generates costs from:

• Clinical development and long-term follow-up.
• Chemistry, manufacturing, and controls work.
• FDA interactions and regulatory submissions.
• Commercial preparation for a rare-disease launch.
• Patient identification, diagnosis, and field-based support.

Revenue remains zero or immaterial unless the sponsor receives milestone payments, licensing income, grants, or limited access-program payments.

Launch phase

If approved, revenue could ramp quickly because Menkes patients have few standardized alternatives. Launch economics would depend on:

• High-touch patient identification.
• Neonatal and genetic-testing networks.
• Specialty distribution.
• Payer contracting.
• Caregiver training for subcutaneous administration.
• Early treatment protocols.

The small population limits sales and marketing scale. A large commercial infrastructure would be inefficient unless the sponsor uses the same platform for other rare metabolic diseases.

Mature phase

At maturity, the product could become a stable niche franchise with low unit volume and high gross margin. Long-term risks include:

• Mortality and limited prevalence.
• Delayed diagnosis.
• Treatment discontinuation.
• Off-label use of lower-cost copper products.
• International reimbursement restrictions.
• Competition from gene therapy or other ATP7A-directed approaches.

The most important financial metric is likely not peak sales alone. It is the ratio of lifetime revenue per patient to acquisition and support costs. In an ultra-rare disease, patient-finding expenses can materially reduce net profitability even when list pricing is high.

Which companies are challenging copper histidinate?

No established generic challenger or biosimilar competitor was identified. Copper histidinate is a small-molecule coordination compound, so biosimilar competition is not the relevant pathway.

Potential competitive threats include:

• Compounded copper preparations.
• Institutional use of alternative parenteral copper products.
• A 505(b)(2) applicant using a different copper salt or formulation.
• Academic or biotech gene-therapy programs targeting ATP7A.
• Diagnostic advances that alter treatment timing and patient selection.

The principal competitive advantage for CUTX-101 is likely commercial standardization, not a large technological gap over every existing copper-replacement approach.

What patent litigation and settlement risks exist?

No public patent litigation or Paragraph IV settlement was established for copper histidinate in the record reviewed. Litigation risk would rise after approval if the sponsor lists patents covering the formulation or method of use.

The most likely disputes would involve:

• Whether a competing injectable formulation falls within formulation claims.
• Whether a generic or 505(b)(2) applicant can avoid method-of-use claims.
• Whether manufacturing claims are valid and enforceable.
• Whether an alternative copper salt is sufficiently different to avoid infringement.
• Whether orphan-drug exclusivity blocks the competing indication.

Because the market is small, a settlement could be more economically rational than prolonged litigation. A launch date agreement would depend on remaining patent life, orphan exclusivity, and the entrant’s expected patient share.

How does copper histidinate compare with other orphan-drug opportunities?

Copper histidinate has a smaller patient population than most commercial orphan drugs but a stronger unmet-need profile. Its investment profile differs from that of an oncology or immunology orphan product.

Metric	Copper histidinate	Typical rare-disease specialty drug
Patient population	Extremely small	Small to moderate
Treatment timing	Often neonatal or early infant	Frequently later in life
Administration	Chronic subcutaneous injection	Varies
Competition	Alternative copper preparations and future gene therapy	Often multiple branded products
Pricing potential	High, but limited by tiny population	High
Commercial complexity	Diagnosis and newborn identification	Specialist prescribing and payer access
Patent value	Formulation and use claims	Often composition-of-matter plus use claims
Biosimilar risk	Not applicable before approval	Relevant for biologics

Key Takeaways

• Copper histidinate is an investigational Menkes disease therapy, with CUTX-101 as the leading commercial program.
• The product had no established FDA-approved commercial status or Orange Book listing in the public record reviewed.
• The market is ultra-small, likely involving dozens of new U.S. patients annually and a limited prevalent population.
• High orphan-drug pricing could produce meaningful revenue, but a realistic U.S. revenue range is more likely tens of millions of dollars than hundreds of millions.
• Commercial success depends on early diagnosis, newborn screening, payer coverage, specialty distribution, and caregiver acceptance of chronic injections.
• Patent protection is likely to center on formulation, dosing, method of use, and manufacturing rather than a broad, durable composition-of-matter monopoly.
• No public Paragraph IV challenge, generic litigation, biosimilar program, or settlement was established.
• The principal long-term competitive threat is a better ATP7A-directed therapy, particularly gene therapy, rather than conventional biosimilar competition.

FAQs

Is copper histidinate commercially available?

A standardized FDA-approved commercial product was not established in the public record reviewed. Access has historically depended on investigational, compassionate-use, institutional, or specialized copper-replacement pathways.

Is CUTX-101 the same as copper histidinate?

CUTX-101 is the development program and proposed pharmaceutical product based on copper histidinate for Menkes disease. The commercial formulation, dosing, and manufacturing specifications are controlled by the sponsor’s development program.

Can a generic manufacturer copy copper histidinate?

A generic manufacturer would first need an approved reference product and an applicable FDA pathway. Formulation, pharmaceutical-equivalence, manufacturing, method-of-use, and regulatory-exclusivity issues could make a conventional ANDA difficult.

Does copper histidinate have biosimilar risk?

No. Biosimilar rules apply to biologic products. Copper histidinate is a small-molecule coordination compound, so any later competitor would more likely use an ANDA, 505(b)(2), or independent NDA pathway.

What is the main investment risk for copper histidinate?

The main risk is limited commercial scale. Even with approval and high pricing, the patient population is exceptionally small, while diagnosis, manufacturing, regulatory, reimbursement, and patient-support costs remain substantial.

References

Cyprium Therapeutics, Inc. (2023). Corporate and product development disclosures for CUTX-101. Fortress Biotech.

Food and Drug Administration. (2023). Orphan Drug Act: Relevant exclusivity and designation provisions. U.S. Department of Health and Human Services.

Kaler, S. G. (2011). ATP7A-related copper transport disorders. GeneReviews, University of Washington, Seattle.

National Institutes of Health. (n.d.). Menkes disease clinical studies and investigational copper histidinate programs. ClinicalTrials.gov.

U.S. Congress. (1983). Orphan Drug Act, 21 U.S.C. §§ 360aa-360ee.